Bimekizumab is a humanized monoclonal antibody designed to selectively neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). These cytokines are known to promote osteogenic differentiation in human periosteum-derived cells (hPDCs). By targeting IL-17A and IL-17F, Bimekizumab effectively inhibits the inflammation-driven osteogenic differentiation, making it a valuable tool in research focused on inflammatory processes and bone metabolism.
Bimekizumab is a humanized monoclonal antibody designed to selectively neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). These cytokines are known to promote osteogenic differentiation in human periosteum-derived cells (hPDCs). By targeting IL-17A and IL-17F, Bimekizumab effectively inhibits the inflammation-driven osteogenic differentiation, making it a valuable tool in research focused on inflammatory processes and bone metabolism.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
